|
|
|
05 Jun 2008 |
Cytokinetics Announces Clinical Trial Data Related to SB-743921 Presented at the 10th International Conference on Malignant Lymphoma
|
|
04 Jun 2008 |
The GI Company Reports Significant Reduction In Occurrence Of Oral Mucositis In Phase II Study Presented At ASCO
|
|
04 Jun 2008 |
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL
|
|
04 Jun 2008 |
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
|
|
04 Jun 2008 |
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
|
|
04 Jun 2008 |
Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma
|
|
04 Jun 2008 |
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
|
|
04 Jun 2008 |
Bavarian Nordic enters clinical trials with prostate cancer vaccine
|
|
04 Jun 2008 |
BioInvent and ThromboGenics report positive Phase I results for anti-PlGF cancer therapeutic TB-403
|
|
04 Jun 2008 |
Bradmer Receives FDA Approval to Proceed with Phase III Clinical Trial
|
|
03 Jun 2008 |
Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma
|
|
03 Jun 2008 |
Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study
|
|
03 Jun 2008 |
Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer
|
|
03 Jun 2008 |
Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting
|
|
03 Jun 2008 |
Trubion Announces Presentation of Positive TRU-016 Data at ASCO
|
|
03 Jun 2008 |
New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing’s Sarcoma
|
|
03 Jun 2008 |
Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial
|
|
03 Jun 2008 |
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
|
|
03 Jun 2008 |
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
|
|
03 Jun 2008 |
Hana Biosciences' Phase 2 Clinical Trial of Marqibo for Metastatic Uveal Melanoma Meets Clinical Response Criteria to Advance to Full Enrollment
|
|
03 Jun 2008 |
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
|
|
03 Jun 2008 |
Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
|
|
03 Jun 2008 |
New Nexavar(R) Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
03 Jun 2008 |
EMEA provides Guidance on Phase III Design and Approval Requirements
|
|
03 Jun 2008 |
Anti-TGF-beta Antisense AP 12009 shows very good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
|
|
03 Jun 2008 |
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
|
|
03 Jun 2008 |
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
|
|
03 Jun 2008 |
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
|
|
03 Jun 2008 |
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
|
|
03 Jun 2008 |
Stimuvax Phase 1/2 survival data support prior results
|
|
03 Jun 2008 |
Oncogenex reports that low serum clusterin levels were predictive of survival in preliminary analyses of phase 2 study of lead drug candidate OGX-011
|
|
03 Jun 2008 |
Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial
|
|
02 Jun 2008 |
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
|
|
02 Jun 2008 |
Study confirms that Avastin significantly increases chance of living without disease progression in metastatic breast cancer
|
|
02 Jun 2008 |
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
|
02 Jun 2008 |
New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting
|
|
02 Jun 2008 |
Curis Announces GDC-0449 Phase I Clinical Data Presented at American Society of Clinical Oncology Annual Meeting 2008
|
|
02 Jun 2008 |
Wyeth Initiates INTORACT. A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
|
|
02 Jun 2008 |
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
|
|
02 Jun 2008 |
Infinity Announces Clinical Data Confirming Activity and Safety of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Refractory GIST
|
|
02 Jun 2008 |
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
|
|
02 Jun 2008 |
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
|
|
02 Jun 2008 |
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
|
|
02 Jun 2008 |
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
|
|
02 Jun 2008 |
First-In-Man Study of RTA 402 Yields Promising Results in Patients with Advanced Cancers
|
|
02 Jun 2008 |
Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197, Under Development by ArQule
|
|
02 Jun 2008 |
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
|
|
02 Jun 2008 |
Positive data on Antisoma’s ASA404 presented at ASCO
|
|
02 Jun 2008 |
ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642
|
|
02 Jun 2008 |
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
|
| |
|
Results 351 - 400 of 2757 |
